All In Biotech

Drug Trial Radar · NCT04121221

A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS

A Phase III Study in Subjects With Relapsing Forms of Multiple Sclerosis (RMS) to Asses Efficacy, Safety and Tolerability of GA Depot, a Long Acting IM Injection of Glatiramer Acetate, Once Monthly Compared to Placebo

Last checked: Nov 20, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,016 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,016

Actual

Start

Sep 19, 2019

Primary completion

Jun 13, 2023

Study completion Jun 13, 2023

Sponsor

Lead sponsor
Mapi Pharma Ltd.Industry
Sponsor type
Industry
First posted
Oct 9, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with Relapsing Forms of Multiple Sclerosis (RMS) to assess the efficacy, safety and tolerability of GA Depot, a long acting IM injection of glatiramer acetate, administered once every four weeks

Conditions

  • Multiple Sclerosis, Relapsing-Remitting

Interventions

  • GA DepotDrug

    Long acting intramuscular injection of glatiramer acetate, once every 4 weeks

  • PlaceboOther

    IM injection once every 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Relapse Rate (ARR)Time frame: 52 weeks

Locations

112 sites in 10 countries. Site status is shown where the registry gives one.

  • Mapi Pharma Research site 08

    Birmingham, Alabama

  • Mapi Pharma Research site 11

    Cullman, Alabama

  • Mapi Pharma Research site 15

    Pasadena, California

  • Mapi Pharma Research site 14

    Denver, Colorado

  • Mapi Pharma Research site 12

    Washington D.C., District of Columbia

  • Mapi Pharma Research site 17

    Homestead, Florida

  • Mapi Pharma Research site 09

    Miami, Florida

  • Mapi Pharma Research site 01

    Northbrook, Illinois

  • Mapi Pharma Research site 02

    Detroit, Michigan

  • Mapi Pharma Research site 13

    Westerville, Ohio

  • Mapi Pharma Research site 04

    Round Rock, Texas

  • Mapi Pharma Research site 02

    Homyel, Belarus

  • Mapi Pharma Research site 04

    Minsk, Belarus

  • Mapi Pharma Research site 05

    Minsk, Belarus

  • Mapi Pharma Research site 06

    Minsk, Belarus

  • Mapi Pharma Research site 01

    Vitebsk, Belarus

  • Mapi Pharma Research site 07

    Vitebsk, Belarus

  • Mapi Pharma Research site 04

    Banja Luka, Bosnia and Herzegovina

  • Mapi Pharma Research site 06

    Bihać, Bosnia and Herzegovina

  • Mapi Pharma Research site 01

    Sarajevo, Bosnia and Herzegovina

  • Mapi Pharma Research site 03

    Tuzla, Bosnia and Herzegovina

  • Mapi Pharma Research site 14

    Haskovo, Bulgaria

  • Mapi Pharma Research site 10

    Pazardzhik, Bulgaria

  • Mapi Pharma Research site 01

    Pleven, Bulgaria

  • Mapi Pharma Research site 02

    Pleven, Bulgaria

  • Mapi Pharma Research site 03

    Pleven, Bulgaria

  • Mapi Pharma Research site 07

    Pleven, Bulgaria

  • Mapi Pharma Research site 12

    Plovdiv, Bulgaria

  • Mapi Pharma Research site 18

    Rousse, Bulgaria

  • Mapi Pharma Research site 04

    Sofia, Bulgaria

  • Mapi Pharma Research site 05

    Sofia, Bulgaria

  • Mapi Pharma Research site 06

    Sofia, Bulgaria

  • Mapi Pharma Research site 08

    Sofia, Bulgaria

  • Mapi Pharma Research site 11

    Sofia, Bulgaria

  • Mapi Pharma Research site 13

    Sofia, Bulgaria

  • Mapi Pharma Research site 15

    Sofia, Bulgaria

  • Mapi Pharma Research site 16

    Sofia, Bulgaria

  • Mapi Pharma Research site 19

    Sofia, Bulgaria

  • Mapi Pharma Research site 09

    Veliko Tarnovo, Bulgaria

  • Mapi Pharma Research site 17

    Vratsa, Bulgaria

Showing 40 of 112 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.